Manufacturing Of First Batch of Covovax Vaccine Begins: Serum Institute

REPRESENTATIONAL
REPRESENTATIONAL

Serum Institute of India (SII) CEO Adar Poonawalla announced the vaccine maker has begun manufacturing the first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc.

"Excited to witness the first batch of Covovax [developed by @Novavax] being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing. Well done team @seruminstindia," Adar Poonawalla said in a tweet.

 US-based Novavax Inc has a vaccine manufacturing agreement with Serum Institute of India, which also manufactures the Covishield vaccine currently administered in the country.

Novavax's vaccine exhibited a 90.4% overall efficacy in Phase-3 clinical trials.

The vaccine candidate 'NVX-CoV2373' demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial, Novavax said in a statement.

That puts it in the same bracket as two of the frontline vaccines being used in the US and European countries, the ones produced by Pfizer-BioNTech and Moderna, which had efficacy rates of 91.3% and 90% in Phase 3 trials, respectively.

The study enrolled 29,960 participants across 119 sites in the US and Mexico to evaluate efficacy, safety and immunogenicity of the vaccine, it added.

Related Stories

No stories found.

No stories found.
corona-virus>>corona-virus/manufacturing-of-first-batch-of-covovax-vaccine-begins-serum-institute
logo
Pratidin Time
www.pratidintime.com